QMS Medical Allied Services Ltd: Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics: A Closer Look

As of 2 June 2026, QMS Medical’s price-to-earnings (P/E) ratio stands at 16.35, a figure that positions the company favourably within its peer group. This P/E is considerably lower than several competitors such as Prevest Denpro, which trades at a P/E of 22.79, and Nureca, which is priced at an elevated 109.5. The company’s price-to-book value (P/BV) is 1.58, indicating a moderate premium over its book value, consistent with an attractive valuation grade.

Enterprise value to EBITDA (EV/EBITDA) is another key metric where QMS Medical shows strength, with a ratio of 8.53. This compares favourably against peers like Prevest Denpro (15.6) and Raaj Medisafe (15.51), suggesting that QMS Medical is trading at a more reasonable multiple relative to its earnings before interest, taxes, depreciation, and amortisation. The EV to EBIT ratio of 10.06 further supports this valuation stance, indicating operational earnings are reasonably priced.

Comparative Peer Analysis

Within the healthcare services sector, QMS Medical’s valuation metrics place it in an attractive category, especially when juxtaposed with companies classified as risky or expensive. For instance, BPL and KMS Medisurgi are marked as risky due to loss-making status or high valuation multiples, with BPL’s EV/EBITDA at a negative -74.96 and KMS Medisurgi’s P/E at 99.6. Meanwhile, companies like Bandaram Pharma, despite being labelled very attractive, trade at a significantly higher P/E of 131.1, which may deter value-focused investors.

Raaj Medisafe and Shree Pacetronix, also rated very attractive, have P/E ratios close to QMS Medical’s, at 16.04 and 15.17 respectively, but their EV/EBITDA multiples are notably higher, suggesting QMS Medical offers a more balanced valuation profile.

Financial Performance and Returns Context

QMS Medical’s return profile over various periods presents a mixed picture. Year-to-date (YTD), the stock has declined by 4.02%, underperforming the Sensex’s 10.51% drop, which suggests relative resilience. Over the past year, the stock’s return of -2.99% also outpaces the Sensex’s -5.53%, indicating a degree of defensive strength amid broader market volatility.

However, the longer-term three-year return of -34.75% contrasts sharply with the Sensex’s robust 26.48% gain, highlighting challenges the company has faced in sustaining growth momentum. The absence of five- and ten-year return data for QMS Medical limits a full long-term comparative analysis but underscores the importance of valuation improvements in the current context.

Profitability and Efficiency Metrics

Return on capital employed (ROCE) and return on equity (ROE) are critical indicators of operational efficiency and shareholder value creation. QMS Medical’s latest ROCE is 14.20%, while ROE stands at 11.69%. These figures, while modest, are respectable within the healthcare services sector and support the company’s attractive valuation grade. The dividend yield of 0.58% is low but consistent with the company’s micro-cap status and reinvestment needs.

Valuation Grade Upgrade and Market Sentiment

On 20 February 2026, QMS Medical’s Mojo Grade was upgraded from Strong Sell to Sell, reflecting an improvement in valuation attractiveness and possibly better operational outlook. The current Mojo Score of 34.0, while still on the lower side, indicates a cautious but improving sentiment among analysts and investors.

The company’s micro-cap classification and recent day change of -1.60% in share price to ₹86.00 from a previous close of ₹87.40 suggest some short-term volatility, but the 52-week range of ₹68.95 to ₹110.50 provides a broad context for price fluctuations and potential upside.

Implications for Investors

The shift in valuation grade from very attractive to attractive for QMS Medical Allied Services Ltd signals a recalibration of price expectations. Investors should note that while the stock is no longer at its lowest valuation extremes, it remains competitively priced relative to many peers in the healthcare services sector.

Given the company’s moderate P/E and EV/EBITDA multiples, alongside improving profitability metrics, QMS Medical may appeal to value-oriented investors seeking exposure to the healthcare services micro-cap segment. However, the stock’s historical underperformance over the medium term and modest dividend yield warrant a cautious approach.

Comparative analysis suggests that while some peers offer very attractive valuations, they often come with higher risk profiles or stretched multiples. QMS Medical’s balanced valuation and improving Mojo Grade may thus represent a middle ground for investors prioritising risk-adjusted returns.

Conclusion

QMS Medical Allied Services Ltd’s recent valuation parameter changes reflect a nuanced improvement in price attractiveness. The company’s P/E ratio of 16.35 and EV/EBITDA of 8.53 position it favourably against many healthcare services peers, while profitability metrics such as ROCE and ROE support a stable operational outlook.

Despite short-term price volatility and a modest Mojo Score of 34.0, the upgrade from Strong Sell to Sell indicates a positive directional shift. Investors should weigh these valuation improvements against the company’s historical return challenges and sector dynamics before making allocation decisions.

Overall, QMS Medical presents an intriguing proposition for those seeking an attractively valued healthcare services micro-cap with potential for recovery and steady performance in a competitive market environment.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today